FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of medicine and deals with bispecific binding agents for modulating biological activity. Essence of invention includes bispecific binding agent, which is cable of directed action on cancer cells by means of binding domain with high affinity with respect to first marker of cell surface, which does not induce significant biological effect, and binding domain with low affinity, which specifically binds with second marker of cell surface, producing significant and required biological effect. Also claimed are pharmaceutical compositions for treatment of malignant tumour, their application for production of medication and sets for diagnostics and visualisation of tumour.
EFFECT: intensification of antitumor action.
37 cl, 7 ex, 2 tbl
| Title |
Year |
Author |
Number |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 |
2003 |
- Koll' Khans
- Bossenmajer Birgit
- Mjuller Khans-Joakhim
- Slivkovski Mark K.
- Kelsi Stefen Majkl
|
RU2338751C2 |
| PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS |
2003 |
- Krejsh Khans-Georg
- Shmidt Jurgen
|
RU2354402C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES |
2016 |
- Moskaleva Olga Vasilevna
- Ulitin Andrej Borisovich
- Solovev Valerij Vladimirovich
- Zaripova Dina Anvarovna
- Vladimirova Anna Konstantinovna
- Nemankin Timofej Aleksandrovich
- Shmakova Aleksandra Pavlovna
- Shitikova Viktoriya Olegovna
- Artyukhova Marina Vladimirovna
- Diduk Sergej Vasilevich
- Torokhin Andrej Alekseevich
- Krapivin Bogdan Nikolaevich
- Grachev Aleksandr Valerevich
- Ivanov Roman Alekseevich
- Morozov Dmitrij Valentinovich
|
RU2653443C2 |
| HUMANIZED ANTIBODY THAT SHOWS CAPACITY TO BIND ErbB2 AND BLOCK ACTIVATION OF ErbB2 RECEPTOR BY LIGAND (VARIANTS) AND COMPOSITION FOR USING IN CANCER TREATMENT COMPRISING THIS ANTIBODY |
2000 |
- Adams Kamellia U.
- Presta Lenard G.
- Slivkovski Mark
|
RU2270029C2 |
| COMPOSITIONS FOR T-CELL THERAPY WITH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF |
2018 |
- Irvine, Darrell, J.
- Ma, Leyuan
|
RU2819805C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES |
2019 |
|
RU2824391C2 |
| HIGH-AFFINITY ANTI-CD3 ANTIBODIES AND METHODS FOR PRODUCTION AND USE THEREOF |
2020 |
- Pejchal, Robert
- Stein, Caitlin
- Mccreary, Julia
|
RU2831840C2 |
| MULTIVALENT ANTIGEN-BINDING FV MOLECULE |
2011 |
|
RU2613368C2 |
| METHOD FOR SELECTION AND PRODUCTION OF SELECTIVE AND MULTISPECIFIC THERAPEUTIC MOLECULES WITH SPECIFIED PROPERTIES, INCLUDING, AT LEAST TWO, DIFFERENT TARGET GROUPS, AND THEIR APPLICATIONS |
2013 |
- Khajndl Diter
- Khyulsmann Peter Mikhel
- Kalutsa Brigitt
- Kopetski Erkhard
- Niderfellner Gerkhard
- Tifentaler Georg
|
RU2644263C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS |
2018 |
|
RU2800922C2 |
